AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Artivion, Inc.
Video analysis: AORT
All videosNo video analysis for this stock yet. Request one from our team.
News: AORT
Artivion Q2 Earnings Call Highlights
Artivion NYSE: AORT reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while adjusted EBITDA margin declined roughly 90 basis points to 21% amid higher research and development spending and costs related to the Endospan acquisition.
Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript
Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript
Artivion (AORT) Q2 Earnings Meet Estimates
Artivion (AORT) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.24 per share a year ago.
Artivion Reports Second Quarter 2026 Financial Results
Second Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025, an increase of 11% on a GAAP basis and 9% on a non-GAAP constant currency basis Net loss for the second quarter of 2026 was $(13.5) million, or $(0.28) per fully diluted share, and non-GAAP net income was $6.3 million, or $0.13 per fully diluted share Adjusted EBITDA increased 7% to $26.4 million in the second quarter of 2026 compared to $24.8 million in the second quarter of 2025 Announced U.S. FDA PMA Approval of the AMDS Hybrid Prosthesis Completed acquisition of Endospan Ltd. ATLANTA, Aug. 6, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2026.
Artivion to Participate in Upcoming Investor Conferences
ATLANTA, July 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at the InterContinental Boston Hotel.
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
ATLANTA, July 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2026 financial results will be released on Thursday, August 6, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.
Fifth Third Bancorp Buys 123,023 Shares of Artivion, Inc. $AORT
Fifth Third Bancorp lifted its stake in Artivion, Inc. (NYSE: AORT) by 58,029.7% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 123,235 shares of the company's stock after acquiring an additional 123,023 shares during the period. Fifth Third
Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device
AORT's FDA approval for AMDS removes a key hospital adoption hurdle and opens access to an estimated $150 million annual U.S. market.
Similar companies
-
Inspire Medical Systems, Inc.
INSP
·
New York Stock Exchange
Compare
-
Integer Holdings Corporation
ITGR
·
New York Stock Exchange
Compare
-
PROCEPT BioRobotics Corporation
PRCT
·
NASDAQ
Compare
-
Brookdale Senior Living Inc.
BKD
·
New York Stock Exchange
Compare
-
Addus HomeCare Corporation
ADUS
·
NASDAQ
Compare
-
Ardent Health Inc.
ARDT
·
New York Stock Exchange
Compare